



The most widely read and highly cited peer-reviewed neurology journal The Official Journal of the American Academy of Neurology

# Neurology Publish Ahead of Print DOI:10.1212/WNL.000000000207428

# Pearls and Oy-sters: Huntington Disease Presenting as Primary Progressive Aphasia: A Case of Semantics

## Author(s):

Antonia J Clarke, BSc (Hons) LLB (Hons) MBBS (Hons)<sup>1, 2</sup>; David Manser, BSc (Adv), MBBS (Hons)<sup>2</sup>; Ronald Fleischer, GradDipGC<sup>3</sup>; Michael Fulham, MBBS(Hons) FRACP<sup>2,4,5</sup>; Rebekah M Ahmed, MBBS (Hons), FRACP, PhD<sup>1, 2</sup>

Corresponding Author: Antonia J Clarke, antonia.clarke@sydney.edu.au

Affiliation Information for All Authors: 1. Faculty of Medicine and Health, University of Sydney, Sydney, Australia; 2. Department of Neurology, Royal Prince Alfred Hospital, Sydney, Australia; 3. Genetics Department, Royal Prince Alfred Hospital, Sydney, Australia; 4. Department of Molecular Imaging, Royal Prince Alfred Hospital; 5. Faculty of Engineering and Computer Science, University of Sydney.

**Equal Author Contribution:** Clarke AJ and Manser D contributed equally to the manuscript.

*Neurology*® Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes. Videos, if applicable, will be available when the article is published in its final form.

### **Contributions:**

Antonia J Clarke: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Analysis or interpretation of data; Additional contributions: AJC drafted and edited the manuscript, filmed the patient, consented the patient for publication, and submitted the manuscript. - DM drafted and edited the manuscript, obtained results of investigations and filmed the patient. - David Manser RF edited the manuscript and provided expertise regarding genetic testing. - Ronald Fleischer MJF edited the manuscript and provided PET images and details for publication. - Michael J Fulham RA conceptualised and edited the manuscript. - Rebekah M Ahmed

David Manser: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Analysis or interpretation of data; Additional contributions: AJC drafted and edited the manuscript, filmed the patient, consented the patient for publication, and submitted the manuscript. - Antonia J Clarke DM drafted and edited the manuscript, obtained results of investigations and filmed the patient. - RF edited the manuscript and provided expertise regarding genetic testing. - Ronald Fleischer MJF edited the manuscript and provided PET images and details for publication. - Michael J Fulham RA conceptualised and edited the manuscript. - Rebekah M Ahmed

Ronald Fleischer: Drafting/revision of the manuscript for content, including medical writing for content; Additional contributions: AJC drafted and edited the manuscript, filmed the patient, consented the patient for publication, and submitted the manuscript. - Antonia J Clarke DM drafted and edited the manuscript, obtained results of investigations and filmed the patient. - David Manser RF edited the manuscript and provided expertise regarding genetic testing. - MJF edited the manuscript and provided PET images and details for publication. - Michael J Fulham RA conceptualised and edited the manuscript. - Rebekah M Ahmed

Michael Fulham: Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data; Additional contributions: AJC drafted and edited the manuscript, filmed the patient, consented the patient for publication, and submitted the manuscript. - Antonia J Clarke DM drafted and edited the manuscript, obtained results of investigations and filmed the patient. - David Manser RF edited the manuscript and provided expertise regarding genetic testing. - Ronald Fleischer MJF edited the manuscript and provided PET images and details for publication. - RA conceptualised and edited the manuscript. - Rebekah M Ahmed

Rebekah M Ahmed: Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design; Analysis or interpretation of data; Additional contributions: AJC drafted and edited the manuscript, filmed the patient, consented the patient for publication, and submitted the manuscript. - Antonia J Clarke DM drafted and edited the manuscript, obtained results of investigations and filmed the patient. - David Manser RF edited the manuscript and provided expertise regarding genetic testing. - Ronald Fleischer MJF edited the manuscript and provided PET images and details for publication. - Michael J Fulham RA conceptualised and edited the manuscript.

Figure Count: 2

Table Count:

#### Search Terms:

[29] Frontotemporal dementia, [38] Assessment of cognitive disorders/dementia, [98] Trinucleotide repeat diseases, [164] Huntington's disease, [200] Aphasia

#### Acknowledgment:

The authors would like to thank the patient and his family for their generosity in consenting to publication of his case.

#### **Study Funding:**

The authors report no targeted funding.

#### **Disclosure:**

The authors report no disclosures relevant to the manuscript.

### **Preprint DOI:**

**Received Date:** 2022-11-11

**Accepted Date:** 2023-04-04

### Handling Editor Statement:

Submitted and externally peer reviewed. The handling editor was Resident and Fellow Deputy Editor Ariel Lyons-Warren, MD, PhD.

# ABSTRACT

We present a case of semantic variant primary progressive aphasia (PPA) as the presenting feature in a patient with Huntington disease (HD). The patient initially developed progressive language impairment including impaired naming, object knowledge and single word comprehension and then developed chorea and behavioural changes. Magnetic resonance imaging (MRI) of the brain showed left anterior temporal lobe and hippocampal atrophy. A neurological FDG PET/CT showed reduced metabolism in the head of the left caudate nucleus. Huntingtin gene testing revealed an expansion of 39 CAG repeats in one allele. This case outlines the substantial overlap between the clinical presentation of HD and frontotemporal lobar degeneration (FTLD) syndromes and provides commentary on the investigation of these neurodegenerative diseases.

## PEARLS

- Where patients present with overlapping clinical signs, genetic testing can complement structural and functional imaging to provide diagnostic clarity, even in the absence of a known family history.
- Emerging long-read sequencing platforms will allow testing for short tandem repeats in multiple genes in parallel to minimize the need for serial testing.

# **OY-STERS**

- The clinical syndrome of semantic variant primary progressive aphasia can arise from different underlying neurodegenerative pathologies.
- Single gene testing may not be sufficiently comprehensive, and panel testing based on next-generation sequencing technology may not detect disorders caused by short tandem repeats.

## CASE

A 76-year-old Caucasian man was referred for evaluation of a three-year history of language difficulties. The patient's family and colleagues noted he had difficulty with naming and verbal recall. At the time of the initial neurological consultation, history and examination revealed involuntary movements of his fingers and shoulders, as well as impulsive and disinhibited behaviours. Of relevance, there were no stereotypies, hyperorality, visual hallucinations or features of dream enactment. He had a past medical history of localised prostate cancer treated with androgen deprivation therapy as well as osteoarthritis. Both parents died in their 40s due to complications related to alcohol consumption. He had one younger male sibling and five children who were well. He achieved university level education and managed a livestock property before working as a mortgage broker.

The patient scored 37/100 on the Addenbrooke's Cognitive Examination (ACE-III)<sup>1</sup> with points lost in multiple subdomains. Specifically, he scored 14/18 for the attention subdomain, 6/26 for memory, 1/14 for fluency, 3/26 for language and 13/16 for visuospatial function. Confrontational naming, single word comprehension and object knowledge were severely impaired with spared repetition and speech production (Video 1). There were frank choreiform movements of the hands, shoulders, and lower limbs. He had occasional involuntary orobuccal movements with oromandibular dyskinesia and motor impersistence of tongue protrusion. His gait was narrow based and apraxic. There was no bradykinesia or rigidity. Luria sequencing was abnormal, and he had a positive grasp reflex bilaterally. He had no pyramidal signs, weakness, or sensory change.

# [Insert Video 1].

Serological testing for acquired conditions such as metabolic derangements, vitamin deficiencies, infective, autoimmune, and paraneoplastic causes was non-contributory. Magnetic resonance imaging (MRI) of the brain showed marked asymmetric left anterior temporal lobe, left hippocampal and bilateral caudate atrophy. There was also mild to moderate generalised supratentorial atrophy without abnormal white matter signal (Figure 1).

## [Insert Figure 1].

A neurological FDG PET/CT showed asymmetric (left more than right) temporal lobe atrophy with marked glucose hypometabolism. There was reduced metabolism in the head of the left caudate nucleus (Figure 2). *C9ORF72* gene testing showed no pathological repeat expansion in either allele, however testing of the huntingtin (*HTT*) gene revealed an expansion of 39 CAG repeats in one allele and 18 repeats in the other.

# [Insert Figure 2].

The findings of a progressive language disorder, chorea, and behavioural changes, with supportive MRI and PET/CT findings and a borderline repeat expansion in the *HTT* gene, were consistent with Huntington disease (HD). Notably, features consistent with semantic variant primary progressive aphasia (PPA) were noted prior to the emergence of the typical movement disorder. The patient was referred for genetic counselling to consider additional family testing and community support.

## DISCUSSION

Our case describes the semantic variant of PPA as the initial clinical manifestation of HD. HD is typically characterised by the triad of psychiatric changes, cognitive impairment, and a movement disorder due to pathogenic CAG triplet expansions in the *HTT* gene. The patient had atypical presenting symptoms of HD, with clear structural and functional imaging supporting a PPA variant of HD. The semantic subvariant of PPA is characterized by anomia and severely impaired single-word comprehension with sparing of repetition and motor speech<sup>2</sup>.

Language impairment can be a prominent feature in individuals diagnosed with HD and typically progresses with advancing dementia and movement abnormalities<sup>3</sup>. Verbal and letter fluency has been implicated in frontostriatal physiopathology, which occurs early in HD<sup>3-5</sup>. Similarly, impaired performance on word generation tasks may reflect frontostriatal disruption of word retrieval processes as well as executive dysfunction.<sup>3,5,6</sup> As the disease progresses, temporal and parietal cortical atrophy contributes to language dysfunction manifesting as impaired naming and object knowledge <sup>6</sup>. The patient's work as a mortgage broker may have drawn attention to his language impairment earlier in the disease course. At the time of his presentation, the functional and anatomical imaging demonstrated temporal

lobe atrophy, supporting the contribution of cortical degeneration to cognitive symptoms in  $HD^{7,8}$ .

Longer expansions in *HTT* are associated with earlier onset of classic disease<sup>9</sup>. Intermediate expansions of 36-39 repeats are considered 'reduced penetrance' alleles, but the majority of patients with 39 repeats phenoconvert to HD by age 75<sup>9</sup>. Metabolic disorders, inflammatory and paraneoplastic syndromes, as well as a range of genetic neurodegenerative conditions, can mimic the HD clinical presentation<sup>10</sup>. For example, hexanucleotide expansions in the *C90RF72* gene, while usually the major genetic cause of familial and sporadic frontotemporal dementia (FTD), were found to be the most common genetic HD phenocopy in a UK cohort<sup>11</sup>. Conversely, there is limited literature describing the diagnosis of FTLD syndromes in patients with choreiform movement disorders or confirmed HD. Sutovsky et. al. report a patient with genetically confirmed HD presenting with probable behavioural variant frontotemporal dementia (bvFTD)<sup>12</sup>. Dewan et. al. more recently described three patients, two with bvFTD and one with the non-fluent variant of PPA, harbouring the huntingtin CAG repeat expansion following analysis of whole-genome sequence data from over 2000 patients diagnosed with FTD/Amyotrophic Lateral Sclerosis<sup>13</sup>.

Genetic testing using targeted gene panels, whole-exome sequencing or whole-genome sequencing is increasingly available for adult-onset neurodegenerative conditions and can identify pathogenic mutations in multiple potential genes<sup>14</sup>. These technologies utilize next generation sequencing platforms which can miss disease-causing repeat expansions, such as the *C9ORF72* and *HTT* expansions due to the short read length of each fragment. Emerging sequencing technologies harnessing long-read sequencing have the potential to test for multiple tandem repeat expansion disorders simultaneously, including with accurate quantification of expansion length<sup>14</sup>. This technology allows for evaluation of pathogenic expansions in different genes in parallel, in addition to other sequence variants captured by next generation sequencing.

Our case adds to the growing literature supporting the overlap between *HTT* repeat expansions and the FTLD syndromes, including PPA, with recent studies suggesting that neurodegenerative pathologies can potentially coexist<sup>15</sup>. Genetic testing in this case supported the diagnosis of atypical HD, presenting with semantic variant PPA, and prompted further discussion of additional testing of the patient's children. Definitive confirmation of the

underlying neurodegenerative process contributing to this patient's temporal lobe atrophy, however, requires post-mortem evaluation.

WNL-2023-000266\_vid1 ---- http://links.lww.com/WNL/C828

# **VIDEO AND FIGURES**


# (VIDEO FILE ATTACHED SEPARATELY)

**Video 1:** The patient is asked to describe his breakfast and then describes the Cookie Theft Picture. Note the fluent speech with impaired naming and object knowledge. There are choreiform movements of the hands and shoulders.

# Figure 1

## MRI brain.

Anterior temporal lobes shown in coronal plane on T1-weighted (A) and T2-weighted (B) MR sequences. There is asymmetrical atrophy of the left mesial temporal lobe with corresponding enlargement of the temporal horn of the lateral ventricle. There is also volume loss of the left frontal lobe with prominence of the sulcal spaces around the frontal and temporal lobes.




## Figure 2

Paired FDG PET/CT imaging.

Paired FDG PET/CT transaxial (top row) and coronal (bottom row) images at the level of the basal ganglia (A, C) and inferior temporal lobes (B, D). In A and C there is markedly reduced glucose metabolism in head of left caudate nucleus and putamen (arrowheads) with asymmetric enlarged frontal and left occipital horns (arrows) and hypometabolism in both anterior temporal lobes (left > right, star). In B and D there is marked temporal lobe atrophy

(left > right, star) with enlargement of left temporal and frontal horns (arrow) and corresponding markedly reduced metabolism in both temporal lobes (left > right, star).



Copyright © 2023 American Academy of Neurology. Unauthorized reproduction of this article is prohibited

# REFERENCES

- So M, Foxe D, Kumfor F, Murray C, Hsieh S, Savage G, Ahmed RM, Burrell JR, Hodges JR, Irish M, Piguet O. Addenbrooke's Cognitive Examination III: Psychometric Characteristics and Relations to Functional Ability in Dementia. J Int Neuropsychol Soc. 2018;Sep 24(8):854-863. doi: 10.1017/S1355617718000541
- Gorno-Tempini ML, Hillis AE, Kertesz A, Mendez M, Cappa SF et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006–1014. doi: <u>10.1212/WNL.0b013e31821103e6</u>
- Gagnon M, Barrette J, Macoir J. Language disorders in Huntington disease: A systematic literature review. Cogn Behav Neurol. 2018;31(4):179-192. doi: 10.1097/WNN.00000000000171

- Ho AK, Sahakian BJ, Robbins TW, Barker RA, Rosser AE, Hodges JR. Verbal fluency in Huntington's disease: a longitudinal analysis of phonemic and semantic clustering and switching. Neuropsychologia 2002;40(8):1277–1284. doi:10.1016/s0028-3932(01)00217-2.
- Hodges JR, Salmon DP, Butters N. Differential impairment of semantic and episodic memory in Alzheimer's and Huntington's diseases: a controlled prospective study. JNNP 1990:53:1089-1095. doi: <u>10.1136/jnnp.53.12.1089</u>
- Garcia AM, Bocanegra Y, Herrera E, Pino M, Munoz E et al. Action-semantic and syntactic deficits in subjects at risk for Huntington's disease. J Neuropsychol. 2018;12:389–408. doi: 10.1111/jnp.12120
- Johnson EB, Ziegler G, Penny W, Rees G, Tabrizi SJ, et al. Dynamics of cortical degeneration over a decade in Huntington's disease. Biol Psychiatry 2021;89(8):807-816 doi: <u>10.1016/j.biopsych.2020.11.009</u>
- 8. Sampedro F, Martinez-Horta S, Perez-Perez J, Horta-Barba A, Lopez-Mora DA, et al. Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-

stage Huntington's disease. Eur J Nuc Med and Mol Imag 2019;46:1111-1116 doi: 10.1016/j.nicl.2020.102415

- 9. McDonnell EI, Wang Y, Goldman J, Marder K. Age of onset of Huntington's disease in carriers of reduced penetrance alleles. Movement Disorders. 2021;36(12):2958-2961.
- Schneider SA, Walker RH, Bhatia KP. The Huntington's disease-like syndromes: what to consider in patients with a negative Huntington's disease gene test. Nat Clin Pract Neurol 2007;3:517-525 doi: <u>10.1038/ncpneuro0606</u>
- Hensman DJ, Poulter M, Beck J, Hehir J, Polke JM, et al. C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology 2014;82:292-299 doi: <u>10.1007/s00401-014-1251-9</u>
- Sutovsky S, Smolek T, Alafuzoff I, Blaho A, Parrak V, et al. Atypical Huntington's disease with the clinical presentation of behavioural variant of frontotemporal dementia. J Neural Transm 2016:123;1423-1433 doi: <u>10.1007/s00702-016-1579-5</u>
- 13. Dewan R, Chia R, Ding J, Hickman RA, Stein TD et al. Pathogenic Huntingtin repeat expansions in patients with frontotemporal dementia and amyotrophic lateral sclerosis. Neuron 2021;109(3):448-460 doi: 10.1016/j.neuron.2020.11.005
- Koriath CAM, Kenny J, Ryan NS, Rohrer JD, Schott JM, et al. Genetic testing in dementia – utility and clinical strategies. Nat Rev Neurol. 2021 Jan;17(1):23-36. doi: 10.1038/s41582-020-00416-1. Epub 2020 Nov 9. PMID: 33168964.
- 15. Forrest S and Kovacs G. Current concepts of mixed pathologies in neurodegenerative diseases. Canadian Journal of Nuerological Sciences / Journal Canadien Des Sciences Neurologiques 2022:1-17. Doi:10.1017/cjn.2022.34



# Pearls and Oy-sters: Huntington Disease Presenting as Primary Progressive Aphasia: A Case of Semantics

Antonia J Clarke, David Manser, Ronald Fleischer GradDipGC, et al. *Neurology* published online May 18, 2023 DOI 10.1212/WNL.00000000207428

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/early/2023/05/18/WNL.000000000207 428.full
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): <b>Aphasia</b> http://n.neurology.org/cgi/collection/aphasia <b>Assessment of cognitive disorders/dementia</b> http://n.neurology.org/cgi/collection/assessment_of_cognitive_disorder s_dementia <b>Frontotemporal dementia</b> http://n.neurology.org/cgi/collection/frontotemporal_dementia <b>Huntington's disease</b> http://n.neurology.org/cgi/collection/huntingtons_disease <b>Trinucleotide repeat diseases</b> http://n.neurology.org/cgi/collection/trinucleotide_repeat_diseases
Permissions & Licensing	Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

# This information is current as of May 18, 2023

٦

*Neurology* <sup>®</sup> is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2023 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

